Trial Profile
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Primary biliary cirrhosis
- Focus Therapeutic Use
- Sponsors Intercept Pharmaceuticals
- 24 Oct 2018 Results of retrospective analysis evaluating the effect of Obeticholic acid on bilirubin from Poise, 201, and 202, presented at the 26th United European Gastroenterology Week.
- 14 Apr 2018 Results of a retrospective analysis assessing the effect of obeticholic acid on bilirubin in patients with high baseline bilirubin from a phase 3 trial (POISE and its open label extension) and two 3-month phase 2 PBO-controlled trials (201, 202 and their open label extensions), presented at The International Liver Congress 2018.
- 10 Oct 2017 Primary endpoint has been met. (Alkaline Phosphatase (AP) Levels), according to results published in the Hepatology.